Hung jury vote leaves FDA with a difficult decision on Durect's non-opioid painkiller
A split advisory panel vote on Durect’s non-opioid drug to manage post-surgical pain is only going to make the FDA’s task harder.
After FDA staff …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
